Browse Studies — Arctuva

Phase 2

A Phase II Study of Pemigatinib Plus Durvalumab (MEDI4736) in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

This is a single arm phase II study of pemigatinib and durvalumab combination in patients with FGFR-2 fusion or rearrangement positive intrahepatic cholangioca…

Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation

Estimated

~$10 – $7,500

Mehmet AkceNCT06728410

Phase 2

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements

This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 1…

Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement

Estimated

~$10 – $8,750

Taiho Oncology, Inc.NCT05727176

Phase 1

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or re…

Mature B-Cell NeoplasmNon Hodgkin LymphomaDLBCL+23 more

Estimated

~$10 – $8,750

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical tria…

Cancer, MetastaticCancerCancer of Pancreas+40 more

Estimated

~$10 – $1,050

Massive Bio, Inc.